Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer; results of a phase 3, randomized, placebo-controlled trial

June 19, 2018

TUCC physician Lawrence Karsh, M.D., was a lead principal investigator in this Phase III, double-blind, randomised, placebo-controlled study of men with non-metastatic castration-resistant prostate cancer at high risk of bone metastasis published in The Lancet in January 2012.

Read Article